An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection
暂无分享,去创建一个
C. Midgley | G. Screaton | S. Yoksan | J. Grimes | C. Simmons | J. Mongkolsapaya | H. Tran | P. Malasit | B. Wills | Martha Bajwa-Joseph | W. Limpitikul | A. Flanagan | A. Cowper | Emily Waiyaiya | Pojchong Chotiyarnwon | Sirijitt Vasanawathana
[1] B. Rouse. Faculty Opinions recommendation of Strategies to alleviate original antigenic sin responses to influenza viruses. , 2012 .
[2] C. Midgley,et al. An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection , 2011, Journal of Virology.
[3] Soila Sukupolvi-Petty,et al. Genotype-Specific Neutralization and Protection by Antibodies against Dengue Virus Type 3 , 2010, Journal of Virology.
[4] R. Rico-Hesse,et al. Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2 , 2010, Journal of Virology.
[5] C. Nelson,et al. The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 , 2010, PLoS pathogens.
[6] Ralph S. Baric,et al. Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses , 2010, PLoS pathogens.
[7] M. Diamond,et al. Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification , 2010, PLoS pathogens.
[8] D. Webster,et al. Progress towards a dengue vaccine. , 2009, The Lancet. Infectious diseases.
[9] R. Jarman,et al. A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model , 2009, PLoS medicine.
[10] M. Accavitti-Loper,et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. , 2009, Virology.
[11] Soila Sukupolvi-Petty,et al. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. , 2009, The Journal of general virology.
[12] G. Chang,et al. Humoral Immune Responses of Dengue Fever Patients Using Epitope-Specific Serotype-2 Virus-Like Particle Antigens , 2009, PloS one.
[13] Gregory D. Gromowski,et al. Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. , 2009, Virology.
[14] M. Guzmán,et al. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. , 2008, Virus research.
[15] G. Chinea,et al. Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. , 2008, Virus research.
[16] Gregory D. Gromowski,et al. Characterization of Dengue Virus Complex-Specific Neutralizing Epitopes on Envelope Protein Domain III of Dengue 2 Virus , 2008, Journal of Virology.
[17] Patrick C. Wilson,et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus , 2008, Nature.
[18] G. Chang,et al. Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II , 2008, Journal of Virology.
[19] J. Roehrig,et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins , 2008, Nature Structural &Molecular Biology.
[20] M. Guzmán,et al. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins , 2008, Archives of Virology.
[21] Gregory D. Gromowski,et al. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. , 2007, Virology.
[22] Gregory D. Gromowski,et al. Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes , 2007, Journal of Virology.
[23] J. Farrar,et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. , 2007, The Journal of infectious diseases.
[24] Gregory D. Gromowski,et al. Solution structure of the envelope protein domain III of dengue-4 virus. , 2007, Virology.
[25] B. Murphy,et al. Prospects for a dengue virus vaccine , 2007, Nature Reviews Microbiology.
[26] M. St. Claire,et al. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention , 2007, Proceedings of the National Academy of Sciences.
[27] Susana Vázquez,et al. Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. , 2006, The American journal of tropical medicine and hygiene.
[28] S. Green,et al. Immunopathological mechanisms in dengue and dengue hemorrhagic fever , 2006, Current opinion in infectious diseases.
[29] G. Nybakken,et al. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody , 2006, Proceedings of the National Academy of Sciences.
[30] E. Konishi,et al. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. , 2006, Vaccine.
[31] Chris Doane,et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus , 2005, Nature Medicine.
[32] G. Air,et al. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. , 2005, Vaccine.
[33] Y. Modis,et al. Variable Surface Epitopes in the Crystal Structure of Dengue Virus Type 3 Envelope Glycoprotein , 2005, Journal of Virology.
[34] Alan L Rothman,et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. , 2004, The Journal of infectious diseases.
[35] Wen Chang,et al. An External Loop Region of Domain III of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells , 2004, Journal of Virology.
[36] Tao Dong,et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever , 2003, Nature Medicine.
[37] Y. Modis,et al. A ligand-binding pocket in the dengue virus envelope glycoprotein , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[38] S. Schilling,et al. Serological Differentiation of Infections with Dengue Virus Serotypes 1 to 4 by Using Recombinant Antigens , 2002, Journal of Clinical Microbiology.
[39] J. H. Strauss,et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion , 2002 .
[40] D. Gubler. The global emergence/resurgence of arboviral diseases as public health problems. , 2002, Archives of medical research.
[41] J. Roehrig,et al. Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells , 2001, Journal of Virology.
[42] G. Murphy,et al. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. , 2001, The American journal of tropical medicine and hygiene.
[43] H. Bedouelle,et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. , 2001, The Journal of general virology.
[44] J. Roehrig,et al. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. , 1998, Virology.
[45] C. Hayes,et al. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. , 1998, The American journal of tropical medicine and hygiene.
[46] S. Yoksan,et al. The micro-focus reduction neutralization test for determining dengue and Japanese encephalitis neutralizing antibodies in volunteers vaccinated against dengue. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[47] C. Lai,et al. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. , 1996, Virology.
[48] S. Nitayaphan,et al. Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR). , 1996, The Southeast Asian journal of tropical medicine and public health.
[49] C. Parrish,et al. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. , 1994, Virology.
[50] R. Belshe,et al. Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin". , 1994, The Journal of infectious diseases.
[51] A. Nisalak,et al. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. , 1989, The American journal of tropical medicine and hygiene.
[52] A. Nisalak,et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.
[53] B. M. Kaufman,et al. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. , 1987, The American journal of tropical medicine and hygiene.
[54] J. Blok. Genetic relationships of the dengue virus serotypes. , 1985, The Journal of general virology.
[55] S J Leach,et al. Original antigenic sin: experiments with a defined antigen. , 1980, Molecular immunology.
[56] S. Halstead. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. , 1979, The Journal of infectious diseases.
[57] SB Halstead,et al. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody , 1977, The Journal of experimental medicine.
[58] S. Halstead,et al. Antibody-enhanced dengue virus infection in primate leukocytes , 1977, Nature.
[59] A. Wilson,et al. Immunological comparison of azurins of known amino acid sequence , 1975, Journal of Molecular Evolution.
[60] S. Cohen,et al. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. , 1970, The Yale journal of biology and medicine.
[61] R. Webster,et al. DISQUISITIONS ON ORIGINAL ANTIGENIC SIN , 1966, The Journal of experimental medicine.
[62] R. Webster,et al. DISQUISITIONS ON ORIGINAL ANTIGENIC SIN , 1966, The Journal of experimental medicine.
[63] R. Webster. Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. , 1966, Journal of immunology.
[64] Thomas Francis,et al. EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS , 1953, The Journal of experimental medicine.
[65] Thomas Francis,et al. INFLUENZA: THE NEWE ACQUAYANTANCE , 1953 .
[66] A. Tokunaga,et al. A Summary of , 2011 .
[67] Gregory D. Gromowski,et al. Short Communication Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III , 2010 .
[68] J. Chin,et al. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. , 2007, Microbes and infection.
[69] A. Nisalak,et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. , 2000, The Journal of infectious diseases.
[70] R. Warren,et al. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. , 1995, Vaccine.
[71] G. Kuno,et al. Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[72] S. Halstead,et al. Original antigenic sin in dengue. , 1983, The American journal of tropical medicine and hygiene.
[73] T. Francis. Influenza: the new acquayantance. , 1953, Annals of internal medicine.
[74] A. Sabin. Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.